BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Azim J, McCurdy H, Moseley RH. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol 2008; 14(38): 5913-5915 [PMID: 18855993 DOI: 10.3748/wjg.14.5913]
URL: https://www.wjgnet.com/1007-9327/full/v14/i38/5913.htm
Number Citing Articles
1
Alberto Quaglia, Eve A. Roberts, Michael Torbenson. MacSween's Pathology of the Liver2024; : 122 doi: 10.1016/B978-0-7020-8228-3.00003-X
2
María Teresa Bordel-Gómez. Porfiria cutánea tarda esporádica por interferón-β1a en un paciente con esclerosis múltiplePiel 2021; 36(7): 498 doi: 10.1016/j.piel.2020.10.015
3
Simone Garcovich, Matteo Garcovich, Rodolfo Capizzi, Antonio Gasbarrini, Maria Assunta Zocco. Cutaneous manifestations of hepatitis C in the era of new antiviral agentsWorld Journal of Hepatology 2015; 7(27): 2740-2748 doi: 10.4254/wjh.v7.i27.2740
4
Lucio J. García-Fraile, Luisa García-Buey, Concepción Alonso Cerezo, Jesús Sanz Sanz, Ignacio de los Santos Gil. Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antiviralsGastroenterología y Hepatología 2022; 45(4): 249 doi: 10.1016/j.gastrohep.2021.09.001
5
F. Ryan Caballes, Hossein Sendi, Herbert L. Bonkovsky. Hepatitis C, porphyria cutanea tarda and liver iron: an updateLiver International 2012; 32(6): 880 doi: 10.1111/j.1478-3231.2012.02794.x
6
Anna Linda Zignego, Manuel Ramos-Casals, Clodoveo Ferri, David Saadoun, Luca Arcaini, Dario Roccatello, Alessandro Antonelli, Anne Claire Desbois, Cloe Comarmond, Laura Gragnani, Milvia Casato, Peter Lamprecht, Alessandra Mangia, Athanasios G Tzioufas, Zobair M Younossi, Patrice Cacoub. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statementAutoimmunity Reviews 2017; 16(5): 523 doi: 10.1016/j.autrev.2017.03.004
7
Çetin Karaca. Viral Hepatitis: Chronic Hepatitis C2019; : 183 doi: 10.1007/978-3-030-03757-4_10
8
E. Delaporte, S. Buche, F. Piette. Manifestaciones cutaneomucosas de las enfermedades hepatobiliares y pancreáticasEMC - Dermatología 2012; 46(1): 1 doi: 10.1016/S1761-2896(12)60832-2
9
Alberto Quaglia, Eve A. Roberts, Michael Torbenson. Macsween's Pathology of the Liver2018; : 111 doi: 10.1016/B978-0-7020-6697-9.00003-0
10
Ashwani K. Singal, Krishna V.R. Venkata, Sarat Jampana, Fakhar-Ul Islam, Karl E. Anderson. Hepatitis C Treatment in Patients With Porphyria Cutanea TardaThe American Journal of the Medical Sciences 2017; 353(6): 523 doi: 10.1016/j.amjms.2017.03.007
11
Taoufik Amezyane, Ali Abouzahir, Jamal Fatihi, Youssef Sekkach, Fatima Mahassin, Omar Sedrati, Driss Ghafir, Victor Ohayon. A Sclerodermiform Porphyria Cutanea TardaInternal Medicine 2010; 49(2): 205 doi: 10.2169/internalmedicine.49.2888
12
L.E. Wiznia, M.E. Laird, A.G. Franks. Hepatitis C virus and its cutaneous manifestations: treatment in the direct‐acting antiviral eraJournal of the European Academy of Dermatology and Venereology 2017; 31(8): 1260 doi: 10.1111/jdv.14186
13
Suzanne Tintle, Ali Alikhan, Mary E. Horner, Jennifer L. Hand, Dawn Marie R. Davis. Cutaneous porphyrias part II: treatment strategiesInternational Journal of Dermatology 2014; 53(1): 3 doi: 10.1111/ijd.12016
14
M.M. Hatch, Z. Nawas, R. Kollipara, S.K. Tyring. Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients?Journal of the European Academy of Dermatology and Venereology 2017; 31(4) doi: 10.1111/jdv.13936
15
Uyen Ngoc Mui, Christopher T. Haley, Ramya Vangipuram, Stephen K. Tyring. Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and preventionJournal of the American Academy of Dermatology 2019; 81(1): 23 doi: 10.1016/j.jaad.2018.10.072
16
U. Floristán, R. Feltes, P. Ramírez-Marín, P. Herranz-Pinto. Interferón alfa y virus hepatitis C: la piel importaRevista Clínica Española 2011; 211(2): 92 doi: 10.1016/j.rce.2010.05.026
17
Richard J. Thompson, Bernard C. Portmann, Eve A. Roberts. MacSween's Pathology of the Liver2012; : 157 doi: 10.1016/B978-0-7020-3398-8.00004-0
18
E. Delaporte, S. Buche, F. Piette. Manifestations cutanéomuqueuses des affections hépatobiliaires et pancréatiquesEMC - Dermatologie 2011; 6(4): 1 doi: 10.1016/S0246-0319(11)57958-0
19
Andrew Aronsohn, Donald Jensen. HCV Eradication: Implications for Disease ResolutionCurrent Hepatitis Reports 2011; 10(1): 27 doi: 10.1007/s11901-010-0076-9
20
Michael W. Fried, Jama M. Darling, Stanley M. Lemon. Schiff's Diseases of the Liver2017; : 628 doi: 10.1002/9781119251316.ch25
21
Nancy S. Handler, Marc Z. Handler, Matthew P. Stephany, Glenn A. Handler, Robert A. Schwartz. Porphyria cutanea tarda: an intriguing genetic disease and markerInternational Journal of Dermatology 2017; 56(6) doi: 10.1111/ijd.13580
22
Nora V. Bergasa. Clinical Cases in Hepatology2022; : 163 doi: 10.1007/978-1-4471-4715-2_6
23
Jama M. Darling, Stanley M. Lemon, Michael W. Fried. Schiff's Diseases of the Liver2011; : 582 doi: 10.1002/9781119950509.ch25
24
Lucio J. García-Fraile, Luisa García-Buey, Concepción Alonso Cerezo, Jesús Sanz Sanz, Ignacio de los Santos Gil. Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antiviralsGastroenterología y Hepatología (English Edition) 2022; 45(4): 249 doi: 10.1016/j.gastre.2021.09.007
25
Adriano M. Pellicelli, Aldo Morrone, Luca Barbieri, Arnaldo Andreoli. Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case reportAnnals of Hepatology 2012; 11(6): 951 doi: 10.1016/S1665-2681(19)31424-3